Synthesis of Polysubstituted Imidazo[1,2-a]pyridines
FIGURE 1. Trisubstituted imidazoles and imidazopyrimidines.
TABLE 1. Optimization of Heteroarylation on
6-Chloroimidazo[1,2-a]pyridines 1 and 2
TABLE 2. Results of One-Pot Suzuki/Heteroarylation or
Heteroarylation/Suzuki on 1
reaction time (h)
conv yield
reaction
time
reaction
time
entry R 1 catalyst system
/T (°C)
compd (%)
(%)
% yield
entry catalyst system method
(step 1)
(step 2)
(3/5/6)
1
2
3
4
H
H
Pd(PPh3)4
Pd(OAc)2/PPh3
3/150
2/150
3/150
2/150
3
3
4
4
80
100
45
61
80
29
91
1
2
3
4
Pd(PPh3)4
Aa
1 h 15 min 3 h
0/42/25
Ph Pd(PPh3)4
Ph Pd(OAc)2/PPh3
Bb
3 h
3 h
2 h
1 h 15 min 0/40/23
2 h
3 h
100
Pd(OAc)2/PPh3
A′ a
B′ b
53/0/20
51/0/22
a One-pot Suzuki/heteroarylation. b One-pot heteroarylation/Suzuki.
SCHEME 2. Suzuki Cross-Coupling on
6-Chloroimidazo[1,2-a]pyridines 1
developed a one-pot synthesis of these substrates by tandem
cyclization, Suzuki coupling, and heteroarylation reactions using
2-amino-5-bromopyridine as starting material. As far as we
know, the previous published methods toward making 2,3,6-
trisubstituted imidazo[1,2-a]pyridines required four separate
steps: cyclization,18 Suzuki19 or Stille coupling20 at the 6-posi-
tion, preparation of 3-halogenoimidazo[1,2-a]pyridines,2f,21 and
then Suzuki22 or Stille23 coupling at the 3-position. Therefore,
within the area of heteroaromatic systems, palladium is often
used to catalyze only one single reaction; hence, a few examples
of one-pot coupling are known.24
â-amyloid9 and constitute a novel class of orally active
nonpeptide bradykinin B2 receptor antagonists.10 Moreover, the
imidazo[1,2-a]pyridine derivative zolpidem was commercialized
as a hypnotic.11
Recently, new trisubstituted imidazoles and imidazopyrim-
idines have been described as kinase inhibitors (compounds I,
II,12 and V,13 Scheme 1), acyl-COAs (cholesterol O-acyltrans-
ferase) (compound III,14 Figure 1), and ALK5 inhibitors
(compound IV,15 Figure 1). Interestingly, all of these compounds
show strong similarity to 3,6-di- or 2,3,6-tri(hetero)arylimidazo-
[1,2-a]pyridines VI (Figure 1). For this reason, we focused our
attention on an expeditious approach to compounds VI.
In continuation with our research on imidazo[1,2-a]pyridine
derivatives,1,16 we recently reported a versatile ring transforma-
tion providing access to 3-(hetero)arylimidazo[1,2-a]pyridines.17
In this paper, we report a microwave-assisted one-pot Suzuki/
heteroarylation preparation of 2,3,6-tri(hetero)arylimidazo[1,2-
a]pyridines from 6-halogeno-2-substituted imidazo[1,2-a]-
pyridines, boronic acids, and heteroaryl bromides. We have also
Results and Discussion
One-Pot Suzuki/Heteroarylation or Heteroarylation/Su-
zuki on 6-Chloroimidazo[1,2-a]pyridines. The required imi-
(13) Dodd, J. H.; Henry, J. R.; Rupert, K. C. PCT Int. Appl. WO 01/
34605; Chem. Abst. 2001, 134, 366888.
(14) Astles, P. C.; Ashton, M. J.; Bridge, A. W.; Harris, N. V.; Hart, T.
W.; Parrott, D. P.; Porter, B.; Riddel, D.; Smith, C.; Williams, R. J. J. Med.
Chem. 1996, 39, 1423.
(15) Callahan, J. F.; Burgess, J. L.; Fornwald, J. A.; Gaster, L. M.;
Harling, J. D.; Harrington, F. P.; Heer, J.; Kwon, C.; Lehr, R.; Mathur, A.;
Olson, B. A.; Weinstock, J.; Laping, N. J. J. Med. Chem. 2002, 45, 999.
(16) (a) El Kazzouli, S.; Berteina-Raboin, S.; Mouaddib, A.; Guillaumet,
G. Tetrahedron Lett. 2003, 45, 3193. (b) El Kazzouli, S.; Berthaut, A.;
Berteina-Raboin, S.; Mouaddib, A.; Guillaumet, G. Lett. Org. Chem. 2005,
2, 184.
(8) Fuchs, K.; Romig, M.; Mendla, K.; Briem, H.; Fechteler, K. WO 14
131; Chem. Abstr. 2002, 136, 183824r.
(9) Zhuang, Z. P.; Kung, M. P.; Wilson, A.; Lee, C. W.; Plo¨ssl, K.; Hou,
C.; Holtzman, D. M.; Kung, H. F. J. Med. Chem. 2003, 46, 237.
(10) Abe, Y.; Kayakiri, H.; Satoh, S.; Inoue, T.; Sawada, Y.; Imai, K.
H. J. Med. Chem. 1998, 41, 564.
(17) Koubachi, J.; El Kazzouli, S.; Berteina-Raboin, S.; Mouaddib, A.;
Guillaumet, G. Synlett. 2006, 3237.
(18) Gueiffier, A.; Mavel, S.; Lhassani, M.; Elhakmaoui, A.; Snoeck,
R.; Andrei, G.; Chavignon, O.; Teulade, J.-C.; Witvrouw, M.; Balzarini,
J.; De Clercq, E.; Chapat, J.-P. J. Med. Chem. 1998, 41, 5108.
(19) Enguehard, C.; The´ry, I.; Hervet, M.; Renou, J. L.; Fauvelle, F.;
Gueiffier, A. HelV. Chim. Acta 2001, 84, 3610.
(20) Hervet, M.; The´ry, I.; Gueiffier, A.; Enguehard, C. HelV. Chim. Acta
2003, 86, 3461.
(21) (a) Paolini, J. P.; Robins, R. K. J. Org. Chem. 1965, 30, 4085. (b)
Fischer, M. H.; Lusi, A. J. Med. Chem. 1972, 15, 982. (c) Hand, E. S.;
Paudler, W. W. J. Org. Chem. 1978, 43, 2900. (d) Gudmundsson, K. S.;
Drach, J. C. Tetrahedron Lett. 1996, 37, 6275.
(11) Holm, K. J.; Goa, K. L. Drugs 2000, 59, 865.
(12) (a) Wilson, K. P.; McCaffrey, P. G.; Hsiao, K.; Pazhanisamy, S.;
Galillo, V.; Bemis, G. W.; Fitzgibbn, M. J.; Caron, P. R.; Murcko, M. A.;
Su, M. S. Chem. Biol. 1997, 4, 423. (b) McLay, I. M.; Halley, F.; Souness,
J. E.; McKenna, J.; Benning, V.; Birrel, M.; Burton, B.; Belvisi, M.; Collis,
A.; Constan, A.; Foster, M.; Hele, D.; Jayyosi, Z.; Kelly, M.; Maslen, C.;
Miller, G.; Ouledlhkim, M. C.; Page, K.; Phipps, S.; Pollock, K.; Porter,
B.; Ratcliffe, A. J.; Redford, E. J.; Webber, S.; Slater, B.; Thybaud, V.;
Wilsher. Bioorg. Med. Chem. 2001, 9, 537.
(22) Enguehard, C.; Renou, J. L.; Collot, V.; Hervet, M.; Rault, S.;
Gueiffier, A. J. Org. Chem. 2000, 65, 6572.
J. Org. Chem, Vol. 72, No. 20, 2007 7651